Gabelli Weighs in on Tetraphase Pharmaceuticals, Inc.’s FY2017 Earnings (NASDAQ:TTPH)

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) – Investment analysts at Gabelli boosted their FY2017 EPS estimates for shares of Tetraphase Pharmaceuticals in a research note issued on Wednesday. Gabelli analyst K. Kedra now forecasts that the biopharmaceutical company will earn ($2.45) per share for the year, up from their prior forecast of ($2.55). Gabelli also issued estimates for Tetraphase Pharmaceuticals’ FY2018 earnings at ($2.00) EPS and FY2021 earnings at ($1.30) EPS.

Other equities research analysts also recently issued research reports about the stock. BMO Capital Markets reiterated a “buy” rating and issued a $12.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Friday, May 5th. Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $8.00 to $15.00 in a research report on Wednesday. HC Wainwright initiated coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 target price for the company. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Thursday. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Tetraphase Pharmaceuticals currently has an average rating of “Buy” and an average price target of $10.25.

TRADEMARK VIOLATION WARNING: “Gabelli Weighs in on Tetraphase Pharmaceuticals, Inc.’s FY2017 Earnings (NASDAQ:TTPH)” was first posted by BBNS and is owned by of BBNS. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/gabelli-weighs-in-on-tetraphase-pharmaceuticals-inc-s-fy2017-earnings-nasdaqttph-updated/1308262.html.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 6.48 on Friday. The stock’s market capitalization is $245.95 million. Tetraphase Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $9.93. The stock’s 50 day moving average is $7.45 and its 200 day moving average is $6.85.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.19. Tetraphase Pharmaceuticals had a negative net margin of 1,932.24% and a negative return on equity of 60.55%. The company had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.46 million. During the same period in the prior year, the firm earned ($0.46) earnings per share. The firm’s quarterly revenue was down 24.5% on a year-over-year basis.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Tetraphase Pharmaceuticals by 16.4% in the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock worth $15,061,000 after buying an additional 230,420 shares during the last quarter. Tekla Capital Management LLC raised its position in Tetraphase Pharmaceuticals by 422.2% in the first quarter. Tekla Capital Management LLC now owns 1,004,322 shares of the biopharmaceutical company’s stock worth $9,230,000 after buying an additional 812,000 shares during the last quarter. State Street Corp raised its position in Tetraphase Pharmaceuticals by 1.6% in the fourth quarter. State Street Corp now owns 710,982 shares of the biopharmaceutical company’s stock worth $2,864,000 after buying an additional 11,391 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Tetraphase Pharmaceuticals by 180.4% in the first quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock worth $5,829,000 after buying an additional 408,078 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Tetraphase Pharmaceuticals by 108.2% in the first quarter. Acadian Asset Management LLC now owns 379,049 shares of the biopharmaceutical company’s stock worth $3,482,000 after buying an additional 197,022 shares during the last quarter. Institutional investors and hedge funds own 46.24% of the company’s stock.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras


Leave a Reply

 
© 2006-2017 BBNS.